To discuss the clinical experiences with XIPERE and microneedle technology for treating uveitis.
Approach:
Interview with Dr. Chin Yee: Dr. Chin Yee shares insights on the use of XIPERE and microneedle technology for delivering treatment directly into the suprachoroidal space.
Key Findings:
XIPERE is an FDA-approved corticosteroid that can be delivered directly into the suprachoroidal space using microneedle technology.
This delivery method allows for better targeting of inflammation in the macula and potentially reduces side effects associated with traditional steroid treatments.
Interpretation:
The suprachoroidal space is an important target for treatment as it allows for direct access to the source of inflammation in uveitis.
Limitations:
There may be a learning curve associated with the new microneedle technology.
Funding for research in this area can be challenging.
Conclusion:
Collaboration between engineering and medicine is crucial for advancing ophthalmic innovations and improving patient outcomes.
